Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
A Grim Reality Strikes Individuals Discontinuing GLP-1 Medications - Featured image
Health

A Grim Reality Strikes Individuals Discontinuing GLP-1 Medications

Numerous individuals achieving weight reduction on GLP-1 agonists encounter challenges in ceasing the treatments, as appetite surges and weight rebounds. Studies indicate significant regain for those stopping, prompting some to view obesity as a chronic issue requiring ongoing medication. However, adopting healthier habits can help maintain losses post-treatment.

Shotlee·January 4, 2026·Updated Jan 27, 2026·2 min read
Share:

Challenges in Discontinuing GLP-1 Treatments

A significant number of individuals who effectively shed pounds using Ozempic and similar GLP-1 agonist medications struggle to taper off the injections, as reported by the BBC. Hunger returns fiercely, causing weight to gradually increase once more, suggesting users may become reliant on these substances for life.

Tanya Hall, a Wegovy recipient unable to discontinue the medication, shared with the outlet: "Throughout my initial 38 years, I battled excess weight—now, I'm 38kg (83 pounds) lighter." She added, "This means a portion of me senses an attachment to continue, as it grants me a sense of command over my situation."

Studies support this, demonstrating that those halting these drugs frequently regain a substantial portion of their lost mass. Celebrities such as Oprah have expressed intentions to remain on them perpetually, as she revealed to People Magazine recently. The takeaway is that numerous individuals might need to manage obesity as a persistent ailment, relying on these drugs indefinitely.

"It will be a permanent commitment," Oprah stated. "I take medication for hypertension, and stopping it elevates my blood pressure. I've come to understand the same applies here—I require it."

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

For those who successfully stop, they typically regain roughly two-thirds of their shed pounds, based on investigations by Ozempic producer Novo Nordisk. Dr. Hussain Al-Zubaidi informed the BBC that he has observed patients recovering 60 to 80 percent of their prior weight losses.

Despite appearances of futility, there is optimism, according to Al-Zubaidi. He recommends developing an "exit plan" involving the adoption of better lifestyle adjustments during treatment. These changes can preserve weight reduction after fully stopping the medications. Health tracking apps like Shotlee can assist in monitoring these new habits effectively.

This proved true for Ellen Ogley, who recounted to the BBC losing 48.5 pounds on Eli Lilly's GLP-1 drug Mounjaro. During her time on it, she cultivated improved dietary routines and integrated physical activity. Even after several months without the medication, she has sustained her progress.

"I aim to inform others that existence beyond Mounjaro can indeed endure," she remarked.

Original source: Yahoo! Health

View original article →
#GLP-1 drugs#weight loss#medication dependency#obesity treatment#lifestyle changes
  1. Home
  2. Blog
  3. A Grim Reality Strikes Individuals Discontinuing GLP-1 Medications

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report
Metabolic Health

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community